OnKure Therapeutics, Inc.
OKUR
$3.90
$0.000.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 41.73% | 110.38% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.96% | 48.32% | -- | -- | -- |
| Operating Income | -18.96% | -48.32% | -- | -- | -- |
| Income Before Tax | -12.99% | -42.00% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.99% | -42.00% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.99% | -42.00% | -- | -- | -- |
| EBIT | -18.96% | -48.32% | -- | -- | -- |
| EBITDA | -19.15% | -48.80% | -- | -- | -- |
| EPS Basic | 96.11% | 95.75% | -- | -- | -- |
| Normalized Basic EPS | 96.03% | 95.74% | -- | -- | -- |
| EPS Diluted | 96.11% | 95.75% | -- | -- | -- |
| Normalized Diluted EPS | 96.03% | 95.74% | -- | -- | -- |
| Average Basic Shares Outstanding | 294.03% | 272.70% | -- | -- | -- |
| Average Diluted Shares Outstanding | 294.03% | 272.70% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |